Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cardiology
Pharmaceutical company comments on results of coronary artery disease study
December 12th, 2004
King Pharmaceuticals reported that data from the Prevention of Events with Angiotensin-Converting-Enzyme Inhibitors (PEACE) trial released at the recent American Heart Association meeting failed to demonstrate that trandolapril confers a therapeutic benefit for patients with stable coronary artery disease or slightly reduced left ventricular function. PEACE is a large-scale, randomized, placebo-controlled clinical trial that evaluated the benefits of adding angiotensin-converting-enzyme (ACE) inhibitor trandolapril 4 mg to modern conventional therapy. King also said that conversely, data from the Heart Outcomes Prevention Evaluation (HOPE) trial,...
Source: Medical Letter on the CDC & FDA (2004-12-12)
|
